Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Chubb
Boehringer Ingelheim
Teva
US Department of Justice
UBS
Merck
McKinsey
Moodys
Harvard Business School

Generated: February 25, 2018

DrugPatentWatch Database Preview

Allergan Company Profile

« Back to Dashboard

What is the competitive landscape for ALLERGAN, and when can generic versions of ALLERGAN drugs launch?

ALLERGAN has one hundred and twenty-one approved drugs.

There are one hundred and sixty-one US patents protecting ALLERGAN drugs and there have been four Paragraph IV challenges on ALLERGAN drugs in the past three years.

There are one thousand four hundred and forty-five patent family members on ALLERGAN drugs in sixty-eight countries and one hundred and thirty-one supplementary protection certificates in fourteen countries.

Summary for Allergan
International Patents:1445
US Patents:161
Tradenames:103
Ingredients:80
NDAs:121

Drugs and US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Allergan Sales Llc BREVICON 28-DAY ethinyl estradiol; norethindrone TABLET;ORAL-28 017743-001 Approved Prior to Jan 1, 1982 AB RX No No ➤ Sign Up ➤ Sign Up
Allergan Inc RHOFADE oxymetazoline hydrochloride CREAM;TOPICAL 208552-001 Jan 18, 2017 RX Yes Yes ➤ Sign Up ➤ Sign Up
Allergan ALBALON naphazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 080248-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Allergan Sales Llc TEFLARO ceftaroline fosamil POWDER;IV (INFUSION) 200327-001 Oct 29, 2010 RX Yes No 7,419,973 ➤ Sign Up Y ➤ Sign Up
Allergan GENOPTIC gentamicin sulfate SOLUTION/DROPS;OPHTHALMIC 062452-001 Oct 10, 1984 AT RX No Yes ➤ Sign Up ➤ Sign Up
Allergan Inc ACZONE dapsone GEL;TOPICAL 207154-001 Feb 24, 2016 RX Yes Yes 9,161,926 ➤ Sign Up Y ➤ Sign Up
Allergan RESTASIS cyclosporine EMULSION;OPHTHALMIC 050790-001 Dec 23, 2002 RX Yes Yes 8,648,048 ➤ Sign Up ➤ Sign Up
Allergan TAZORAC tazarotene CREAM;TOPICAL 021184-001 Sep 29, 2000 RX Yes Yes ➤ Sign Up ➤ Sign Up
Allergan Sales Llc VIIBRYD vilazodone hydrochloride TABLET;ORAL 022567-003 Jan 21, 2011 RX Yes No 7,834,020 ➤ Sign Up Y Y ➤ Sign Up
Allergan ALPHAGAN P brimonidine tartrate SOLUTION/DROPS;OPHTHALMIC 021770-001 Aug 19, 2005 RX Yes Yes 8,858,961*PED ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Allergan

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc CORDRAN flurandrenolide TAPE;TOPICAL 016455-001 Approved Prior to Jan 1, 1982 3,632,740 ➤ Sign Up
Allergan Sales Llc TRELSTAR triptorelin pamoate INJECTABLE;INTRAMUSCULAR 020715-001 Jun 15, 2000 5,134,122 ➤ Sign Up
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 021275-001 Mar 16, 2001 8,017,655 ➤ Sign Up
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-002 Dec 20, 1996 5,212,199 ➤ Sign Up
Allergan Sales Llc ESTRACE estradiol CREAM;VAGINAL 086069-001 Jan 31, 1984 4,436,738 ➤ Sign Up
Allergan ZYMAR gatifloxacin SOLUTION/DROPS;OPHTHALMIC 021493-001 Mar 28, 2003 4,980,470*PED ➤ Sign Up
Allergan Sales Llc RECTIV nitroglycerin OINTMENT;INTRA-ANAL 021359-001 Jun 21, 2011 7,189,761 ➤ Sign Up
Allergan PROPINE dipivefrin hydrochloride SOLUTION/DROPS;OPHTHALMIC 018239-001 Approved Prior to Jan 1, 1982 3,809,714 ➤ Sign Up
Allergan LUMIGAN bimatoprost SOLUTION/DROPS;OPHTHALMIC 022184-001 Aug 31, 2010 6,403,649 ➤ Sign Up
Allergan Sales Llc ALORA estradiol FILM, EXTENDED RELEASE;TRANSDERMAL 020655-001 Dec 20, 1996 5,164,190 ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ALLERGAN drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 20 mg, 40 mg, 80 mg and 120 mg ➤ Subscribe 7/25/2017
➤ Subscribe Tablets 5 mg/80 mg ➤ Subscribe 6/9/2017
➤ Subscribe Gel 7.5% ➤ Subscribe 2/13/2017
➤ Subscribe Capsules 145 mcg and 290 mcg ➤ Subscribe 8/30/2016
➤ Subscribe Tablets 10 mg, 20 mg, and 40 mg ➤ Subscribe 1/21/2015
➤ Subscribe Injection 400 mg/vial and 600 mg/vial ➤ Subscribe 10/29/2014
➤ Subscribe Capsules 140 mg/125 mg/ 125 mg ➤ Subscribe 8/12/2014
➤ Subscribe Ophthalmic Solution 0.25% ➤ Subscribe 7/30/2014
➤ Subscribe Gel 10% ➤ Subscribe 6/19/2014
➤ Subscribe Suppository 1000 mg ➤ Subscribe 5/24/2013
➤ Subscribe Tablets 12.5 mg, 25 mg, 50 mg, and 100 mg ➤ Subscribe 1/14/2013
➤ Subscribe Capsules 4 mg and 8 mg ➤ Subscribe 10/9/2012
➤ Subscribe Tablets 2.5 mg, 5 mg, 10 mg, and 20 mg ➤ Subscribe 12/19/2011
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 8/24/2011
➤ Subscribe Opthalmic Solution 0.45% ➤ Subscribe 8/23/2011
➤ Subscribe Ophthalmic Solution 0.01% ➤ Subscribe 4/5/2011
➤ Subscribe Ophthalmic Solution 0.5% ➤ Subscribe 12/7/2010
➤ Subscribe Topical Solution 0.03% ➤ Subscribe 5/3/2010
➤ Subscribe Extended-release Capsules 60 mg ➤ Subscribe 3/2/2009
➤ Subscribe Ophthalmic Solution 0.03% ➤ Subscribe 12/22/2008
➤ Subscribe Ophthalmic Solution 0.2%/0.5% ➤ Subscribe 11/21/2008
➤ Subscribe Ophthalmic Solution 0.05% ➤ Subscribe 10/14/2008
➤ Subscribe Transdermal System Extended-re 3.9 mg/24 hrs ➤ Subscribe 8/19/2008
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 10/16/2007
➤ Subscribe Ophthalmic Solution 0.30% ➤ Subscribe 7/19/2007
➤ Subscribe Ophthalmic Solution 0.10% ➤ Subscribe 12/20/2006
➤ Subscribe Ophthalmic Solution 0.15% ➤ Subscribe 11/3/2006
➤ Subscribe Capsules 5 mg ➤ Subscribe 8/17/2005
➤ Subscribe Capsules 10 mg and 20 mg ➤ Subscribe 3/30/2005
➤ Subscribe Ophthalmic Solution 0.40% ➤ Subscribe 1/28/2005
Premature patent expirations for ALLERGAN

Expiration due to failure to pay maintenance fee

Patent Number Expiration Date
➤ Sign Up ➤ Sign Up

Non-Orange Book US Patents for Allergan

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,927,552 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
7,910,546 Methods and compositions for the treatment of gastrointestinal disorders ➤ Sign Up
9,580,424 Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt ➤ Sign Up
7,470,433 Formulations for transdermal or transmucosal application ➤ Sign Up
7,387,788 Pharmaceutical compositions of nicotine and methods of use thereof ➤ Sign Up
8,859,604 Crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-- 1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid ➤ Sign Up
8,980,290 Transdermal compositions for anticholinergic agents ➤ Sign Up
8,318,070 Ocular implant made by a double extrusion process ➤ Sign Up
7,147,644 Apparatus for delivery of ocular implants ➤ Sign Up
8,318,744 Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Allergan Drugs

Supplementary Protection Certificates for Allergan Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2009004 Lithuania ➤ Sign Up PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
14/041 Ireland ➤ Sign Up PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
02C/035 Belgium ➤ Sign Up PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
80016 Netherlands ➤ Sign Up PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606
C0009 Belgium ➤ Sign Up PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
2011 00026 Denmark ➤ Sign Up PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
C0036 France ➤ Sign Up PRODUCT NAME: SILODOSIN; REGISTRATION NO/DATE IN FRANCE: EU/1/09/608/001 DU 20100129; REGISTRATION NO/DATE AT EEC: EU/1/09/608/001 DU 20100129
C/GB04/032 United Kingdom ➤ Sign Up PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
C0008 Belgium ➤ Sign Up PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107
330 Luxembourg ➤ Sign Up CERTIFICATE TITLE: UNE COMBINAISON D'OLMESARTAN MEDOXOMIL, OPTIONNELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE ET D'HYDROCHLOROTHIAZIDE (OLMETEC PLUS)
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chinese Patent Office
Deloitte
Express Scripts
Argus Health
Federal Trade Commission
Fish and Richardson
US Army
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot